Lesson plan
KD-414
KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.
Article summary
KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.
Key claims
- release date: 2022 — source: Wikipedia, revision 1301281576, retrieved 2026-10-20 · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the release date is "2022". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia, “KD-414”, revision 1301281576, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1301281576
Key claims and bibliography are generated from the same tracked claims and sources as the article page.